The relationship between growth hormone signaling and aging has long intrigued longevity researchers, but translatable pharmacological tools have remained elusive. A finding from a decades-long transgenic mouse colony now provides the clearest evidence yet that pharmacologically blocking the growth hormone receptor — using a mechanism already embedded in an FDA-approved human drug — can meaningfully extend both median and maximal lifespan, while also reducing frailty markers in aged animals.
The study examined GH receptor antagonist (GHA) transgenic mice, a lineage maintained since 1991 that express a mutated form of GH in which glycine at position 120 is substituted with lysine, converting the hormone from a receptor activator to a competitive blocker. This genetic model directly parallels the molecular basis of Pegvisomant (Somavert), approved for acromegaly treatment in humans. Addressing methodological shortcomings of an earlier negative study, researchers found that male GHA mice lived a median- and maximum-lifespan extension of statistical significance, with females showing especially robust gains — maximal lifespan extended by 265 days (p = 9 × 10⁻⁶). Separately, a cohort of two-year-old GHA mice displayed reduced frailty scores and superior grip strength compared to controls, despite carrying greater adiposity.
These results land in a well-established conceptual landscape. Ames and Snell dwarf mice, which lack functional GH signaling entirely, are among the longest-lived rodent models known. The new data are significant because they demonstrate that receptor-level antagonism — rather than complete hormonal abolition — is sufficient for lifespan extension, a pharmacologically more tractable target. The adiposity increase, however, deserves scrutiny: it may reflect altered IGF-1 and insulin sensitivity, and whether this represents a benign trade-off or a latent metabolic liability in longer-lived animals remains unclear. Critically, this is an animal study; Pegvisomant's poor binding affinity to rodent GH receptors means human extrapolation is biologically plausible but not yet demonstrated. The frailty and grip-strength data are especially compelling for healthspan translation and warrant controlled trials in aged populations.
